Inloggen
Inloggen
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Registreer
Of aanmelden met
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ASCENDIS PHARMA A/S

(ASND)
  Rapport
Vertraagde tijd Nasdaq  -  22:00:00 27-01-2023
122.50 USD   +0.80%
18/01Technologieaandelen leiden Europese aandelen licht hoger in de woensdaghandel
MT
17/01Farmaceutische aandelen leiden Europese aandelen hoger in de dinsdaghandel
MT
17/01Ascendis Pharma A/S : SVB Securities LLC herhaalt koopadvies voor het aandeel
MM
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproductenFonds 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiŽle publicatiesSectornieuws
Nieuws in andere talen op ASCENDIS PHARMA A/S
18/01Tech Stocks Lead European Equities Modestly Higher in Wednesday Trading
17/01Pharma Stocks Lead European Equities Higher in Tuesday Trading
10/01BioAtla Sees Dosing of First Patient in Mid-Stage Part 2 Study in Soft Tissue Cancer Th..
09/01European Equities Begin Week With Sharp Rise
09/01Ascendis Pharma A/s : INCORPORATION BY REFERENCE - Form 6-K
08/01Ascendis Pharma Provides Update on Vision 3x3 Strategic Roadmap at 41st Annual J.P. Mor..
04/01Online Enrollment Now Open for Physicians Requesting Expanded Access to Ascendis Pharma..
03/01Ascendis Pharma A/s : Articles of Association - Form 6-K
03/01Ascendis Pharma to Present at the 41st Annual†J.P. Morgan Healthcare Conference
2022Ascendis Pharma A/s : Articles of Association - Form 6-K
2022After Seesaw Opening, European Equities Little Changed in Monday Trading
2022Ascendis Pharma A/s : INCORPORATION BY REFERENCE - Form 6-K
2022Ascendis Pharma A/S Announces U.S. Food & Drug Administration Allows to Initiate an Exp..
2022Ascendis Pharma to Initiate TransCon™ PTH U.S. Expanded Access Program for Adult ..
2022European Equities Nudge Higher on Slightly Lower Euro Area Inflation
2022Ascendis Pharma to Participate in the 5th Annual Evercore ISI HealthCONx Conference
2022European Equities Flat in Choppy Trade Wednesday as Geopolitical Tensions Weigh
2022Ascendis Pharma Submits Marketing Authorisation Application to the European Medicines A..
2022European ADRs Continue to Trend Higher in Monday Trading
2022Ascendis Pharma Submits Marketing Authorization Application in EU for Hypoparathyroidis..
2022Dose Escalation Data from transcendIT-101 Ascendis Pharma's Phase 1/2 Trial of TransCon..
2022Once-Weekly TransCon CNP Achieved Primary Efficacy Objective, with Superiority at 100 -..
2022Ascendis Pharma A/s : INCORPORATION BY REFERENCE - Form 6-K
2022Ascendis Pharma Submits Marketing Authorisation Application to the European Medicines A..
2022Ascendis Pharma Submits Marketing Authorization Application to the European Medicines A..
2022Ascendis Pharma A/s : TransCon™ CNP ACcomplisH Trial Topline Results
2022Once-Weekly TransCon™ CNP Achieved Primary Efficacy Objective, with Superiority a..
2022TransCon CNP Achieves Primary Efficacy Objective, with Superiority at 100 Ķg/kg/week, i..
2022ADRs End Higher; Ascendis Pharma, ASML Holding Trade Actively
2022Ascendis Pharma A/s : TransCon™ TLR7/8 Agonist Initial Results from Dose Escalation ..
2022Dose Escalation Data from transcendIT-101, Ascendis Pharma's Phase 1/2 Trial of TransCo..
2022Dose Escalation Data from transcendIT-101, Ascendis Pharma’s Phase 1/2 Trial of Tr..
2022Ascendis Pharma A/s : Articles of Association - Form 6-K
2022European Bourses Close Mostly Lower as EU Unemployment Rate Declines
2022European ADRs Regain Some Early Losses on Thursday
2022Ascendis Pharma A/s : INCORPORATION BY REFERENCE - Form 6-K
2022Earnings Flash (ASND) ASCENDIS PHARMA Reports Q3 Revenue EUR15.3M
2022Ascendis Pharma Reports Third Quarter 2022 Financial Results
2022Ascendis Pharma A/S Reports Earnings Results for the Third Quarter and Nine Months Ende..
2022FDA Accepts for Priority Review Ascendis Pharma's NDA for TransCon PTH in Adult Patient..
2022Ascendis Pharma Says FDA Grants Priority Review to Hypoparathyroidism Treatment TransCo..
2022Ascendis Pharma Gets FDA Acceptance for Priority Review of TransCon PTH
2022Ascendis Pharma A/s : INCORPORATION BY REFERENCE - Form 6-K
2022FDA Accepts for Priority Review Ascendis Pharma's NDA for TransCon™ PTH in Adult ..
2022Ascendis Pharma A/S Announces FDA Accepts for Priority Review Its NDA for TransCon(TM) ..
2022Ascendis Pharma A/S Announces Third Quarter 2022 Financial Results and Business Update ..
2022European ADRs Move Higher in Thursday Trading
2022Ascendis Pharma A/s : Articles of Association - Form 6-K
2022European ADRs Move Slightly Lower in Wednesday Trading
2022European ADRs Move Sharply Lower in Wednesday Trading
2022Ascendis Pharma A/s : INCORPORATION BY REFERENCE - Form 6-K
2022European ADRs Surge Higher in Monday Trading
2022Ascendis Pharma Announces Recommended Phase 2 Dose and Cohort Expansion for transcendIT..
2022Ascendis Pharma Announces Recommended Phase 2 Dose and Cohort Expansion for TranscendIT..
2022Ascendis Pharma A/s : Articles of Association - Form 6-K
2022Ascendis Pharma Added to Wedbush Best Ideas List
2022European ADRs Move Lower in Thursday Trading
2022Ascendis Pharma A/s : Articles of Association - Form 6-K
2022Ascendis Pharma A/S Appoints William Carl Fairey Jr. and Siham Imani as Class I Directo..
2022New Long-Term Data in Adult Patients with Hypoparathyroidism Treated with Ascendis Phar..
2022Ascendis Pharma A/S announces new Week 110 data from the Phase 2 PaTH Forward Trial
2022European ADRs Move Slightly Higher in Thursday Trading
2022Ascendis Pharma Submits TransCon PTH New Drug Application to the U.S. FDA for Adult Pat..
2022Ascendis Pharma A/S Announces Upcoming Investor Presentations in September
2022Ascendis Pharma Submits New Drug Application With FDA For Hormone Replacement Drug
2022Ascendis Pharma Submits TransCon™ PTH New Drug Application to the U.S. FDA for Ad..
2022Ascendis Pharma Submits Transcon™ Pth New Drug Application to the U.S. FDA for Adu..
2022European ADRs Move Higher in Thursday Trading
2022European ADRs Move Lower in Wednesday Trading
2022European ADRs Nudge Lower in Tuesday Trading
2022Ascendis Pharma A/s : Notice to convene Extraordinary General Meeting - Form 6-K
2022European ADRs Move Lower in Thursday Trading
2022Ascendis Pharma A/s : Reports Second Quarter 2022 Financial Results - Form 6-K
2022Ascendis Pharma Q2 Loss Shrinks as Revenue Rises
2022Ascendis Pharma A/S Reports Second Quarter 2022 Financial Results
2022Ascendis Pharma A/S Reports Earnings Results for the Second Quarter and Six Months Ende..
2022European ADRs Move Higher in Monday Trading
2022European ADRs Move Lower in Friday Trading
2022Ascendis Pharma A/S Announces Second Quarter 2022 Financial Results and Business Update..
2022European ADRs Move Lower in Tuesday Trading
2022European ADRs Move Lower in Wednesday Trading
2022European ADRs Move Higher in Friday Trading
2022European ADRs Nudge Lower in Tuesday Trading
2022Ascendis Pharma A/S Announces Two Oral Presentations Highlighting the Potential for Tra..
2022European ADRs Move Higher in Tuesday Trading
2022Ascendis Pharma A/S Announces Two Oral Presentations Highlighting the Potential for Tra..
2022European ADRs Move Lower in Friday Trading
2022European ADRs Move Lower in Wednesday Trading
2022European ADRs Move Higher in Friday Trading
2022European ADRs Move Lower in Tuesday Trading
2022Ascendis Pharma - Positive Results from VISEN's Phase 3 Trial of Once-Weekly TransCon h..
2022Positive Results from VISEN's Phase 3 Trial of Once-Weekly TransCon hGH in China Consis..
2022Ascendis Pharma A/S Announces New Commercial Endocrinology Leadership Appointments
2022Ascendis Pharma A/S Announces Positive Results from VISEN’s Phase 3 Trial of Once-..
2022Ascendis Pharma A/S Announces Management Changes
2022Sector Update: Health Care Stocks Close Higher on Thursday
2022Sector Update: Health Care Stocks Still Struggling for Direction Thursday
2022Sector Update: Health Care
2022Ascendis Pharma Q1 Loss Widens, Revenue Rises
2022Ascendis Pharma A/S Reports Earnings Results for the First Quarter Ended March 31, 2022
Volgende evenement op ASCENDIS PHARMA A/S